MAP2K7 and breast carcinoma: Treatment with HER-2 antibody trastuzumab, a phosphatidylinositol 3-kinase inhibitor, or a MEK inhibitor abolished the tumorigenic capacity of the EBV-infected breast cancer cells, indicating the critical role of HER2/HER3 signaling.